Name (Synonyms) | Correlation | |
---|---|---|
drug440 | CNS magnetic resonance imaging (MRI) imaging Wiki | 1.00 |
drug723 | Data collection from lumbar puncture Wiki | 1.00 |
drug1489 | Microscopy of defined brain regions on autopsy specimens Wiki | 1.00 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This study is to analyze the microglia reaction or direct neurotropic effects of CNS COVID-19 in pathogenesis and brain stem dysfunction in critically ill patients. A microglia-focused, brain-specific 50+ marker CODEX panel is used to assess the neuroinflammatory microenvironment in specific brain regions of deceased COVID-19 patients. The peripheral (cerebrospinal fluid and peripheral blood) cytokine response to SARS-CoV-2 is investigated in regard to CNS affection and consecutive blood brain barrier disruption leading to braininherent neuroinflammatory reactions
Description: Comparison of lesions from patients that are neurologically affected to non-affected individuals in terms of CNS involvement to describe encephalitic changes due to COVID-19 infection.
Measure: MRI imaging data Time: Project duration for each patient takes 1 hour for the MRI at baselineDescription: Description of proteomic biomarkers (CSF and Plasma) in comparison with control reference sample.
Measure: Proteomic analysis Time: 10 minutes for blood draw at baselineDescription: Mass cytometry will be performed form peripheral blood mononuclear cells to count cell population frequency.
Measure: Peripheral blood leukocyte Cytof Mass Cytometry Analysis for cell population frequency Time: 10 minutes for blood draw at baselineDescription: In situ distribution assessment of marker expression (CD147 protein, ACE2 protein, Transmembrane protease serine subtype 2 (TMPRSS2))
Measure: CODEX (high dimensional microscopy) workflow analysis of defined regions on brain autopsy specimens Time: at baseline